Labopharm files New Drug Submission with Health Canada for novel antidepressant
LAVAL, QC, Aug. 5 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS ) today announced it has filed a New Drug Submission (NDS) with the Therapeutic Products Directorate of Health Canada for its novel
formulation of the antidepressant trazodone.
"We are pleased to file our New Dru...
Fruitfly Model of a Neuropathic Disease Demonstrates Novel Role for Proteins in the Family of aTyr Pharma's Product Class
SAN DIEGO, July 13 /PRNewswire/ -- Research published in the June 26, 2009 edition of Proceedings of National Academy of Sciences provides further evidence for novel
roles of tRNA synthetases in disease, validating the therapeutic potential for aTyr Pharma's new class of naturally occurring prot...
Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R)
S. MAMEDE DO CORONADO, Portugal, June 29 /PRNewswire/ -- Data presented
today, in Budapest, demonstrated that add-on treatment with the novel,
once-daily anti-epileptic Zebinix(R)* (eslicarbazepine acetate; ESL) resulted
in a marked and sustained decrease in seizure frequency over the long-ter...
CeNeRx BioPharma Obtains Rights to Novel Drug Candidate for Prevention and Treatment of Neurodegeneration Disorders
--Orally Active Enhancer of Human Nerve Growth Factor Has Demonstrated Promising Activity Preclinically--
--Broad Potential Applications Include Neuropathies, Alzheimer's and Huntington's Disease and Others--
RESEARCH TRIANGLE PARK, N.C., June 16 /PRNewswire/ -- CeNeRx BioPharma, Inc., a...
FYI From Human Genome Sciences: GlaxoSmithKline Study Shows GSK's Novel Diabetes Treatment Syncria(R) (Albiglutide) Improves Glucose Control, Reduces Weight
ROCKVILLE, Md. , June 8 /PRNewswire-FirstCall/ -- Attached is a press release issued yesterday by GlaxoSmithKline (GSK), regarding new Phase 2 data for Syncria(R) (albiglutide) presented at the American Diabetes Association 69th Scientific Sessions in New Orleans.
Study Shows GSK's Novel Diabetes Treatment SYNCRIA(R) (albiglutide) Improves Glucose Control and Reduces Weight
LONDON, RESEARCH TRIANGLE PARK, N.C., and NEW ORLEANS, June 7 /PRNewswire-FirstCall/ -- New Phase II data presented today at the American Diabetes Association 69th Scientific Sessions in New Orleans show that the investigational type 2 diabetes treatment Syncria(R) (albiglutide) significantly redu...
Three Surgeons in East Texas Are Successfully Integrating a Novel Stem Cell Procedure for Spine Surgeries
Stem Cell Technologies for Surgery
TEXARKANA, Texas, June 5 /PRNewswire/ -- A new breakthrough in adult stem cell technology has three Texarkana neurosurgeons leading their industry by utilizing concentrated stem cells for spine surgery. The innovative technique is improving the desired resul...
CEL SCI Collaborators Demonstrate Novel L.E.A.P.S. Vaccines Immunize Mice Against Tuberculosis Antigens and Suggest Potential to Treat Swine and Other Influenzas
VIENNA, Va., June 5 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE AMEX: CVM ) announced today that its collaborators at the University of Hawaii reported on data at the annual American Society for Microbiology in Philadelphia, PA. This data demonstrates that vaccines utilizing its L.E.A...
Bayer Announces New Data on Novel Anti-cancer Compound BAY 73-4506
Data Presented at 45th American Society of Clinical Oncology Annual Meeting
Abstracts: 5033, 3560
ORLANDO, Fla., May 30 /PRNewswire/ -- Bayer today announced results from Phase I and II trials of BAY 73-4506, a potent oral multi-kinase inhibitor currently being studied in multiple tumor ...
Chipscreen and HUYA Bioscience to Present Clinical Data on Novel HDAC Inhibitor at the 2009 ASCO Annual Meeting
SHENZHEN, China and SAN DIEGO, May 28 /PRNewswire/ -- Shenzhen Chipscreen Biosciences, Ltd., and HUYA Bioscience International, LLC, today announced that final data from a Phase 1 trial conducted by Chipscreen of the investigational compound chidamide (CS055/HBI-8000) will be presented at the 2009...
Oxford BioTherapeutics and GlaxoSmithKline Form Strategic Alliance to Develop Novel Cancer Therapeutic Antibodies
OXFORD, England, May 18 /PRNewswire/ --
- New Alliance a Key Step for OBT to Broaden its Exciting Pipeline of
Oxford BioTherapeutics (OBT) today announced a strategic alliance with
GlaxoSmithKline to discover, develop and commercialise novel, therapeutic
One Step Closer: Novel Opioid Receptor Compound in Phase I Clinical Trials
TROY, N.Y., May 8 /PRNewswire-USNewswire/ -- For more than 10 years, Mark Wentland, professor of chemistry and chemical biology at Rensselaer Polytechnic Institute , led a Rensselaer team in the discovery of a family of novel
opioid receptor compounds with the potential to treat nervous system di...
ImQuest BioSciences Receives Phase I SBIR Grant to Develop a Novel Hepatitis C Virus Therapeutic Agent
FREDERICK, Md., April 21 /PRNewswire/ -- ImQuest BioSciences and Arisyn Therapeutics jointly announced today the successful acquisition of funding from the National Institutes of Health to support the development of novel
small molecule therapeutics for the treatment of hepatitis C virus (HCV) inf...
VentiRx Pharmaceuticals Initiates Phase I Clinical Trial of VTX-1463, a Novel TLR8 Agonist for the Treatment of Allergic Rhinitis
First Selective TLR8 Agonist to Advance for Treatment of Allergy
SAN DIEGO , April 16 /PRNewswire/ -- VentiRx Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of novel
Toll-Like Receptor 8 (TLR8) agonists for the treatment of cancer, respiratory and inflammatory ...
Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkin's Lymphoma
SUNNYVALE, Calif., April 13 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc.
(Nasdaq: PCYC ) today announced that it has begun treating patients in a Phase
1 dose-escalation study to evaluate the safety and tolerability of PCI-32765,
an orally available, selective inhibitor of Bruton's tyrosine ...
Watson Announces United States Availability of RAPAFLO(TM) (silodosin), a Novel New Treatment in Benign Prostatic Hyperplasia (BPH)
-- New product, now available in pharmacies, will provide rapid symptom relief for number one reason men visit a urologist --
CORONA, Calif., April 7 /PRNewswire-FirstCall/ --Watson Pharmaceuticals, Inc. (NYSE: WPI ), a leading specialty pharmaceutical company, announced today that RA...
Rib-X Pharmaceuticals Novel Antibiotic Delafloxacin Named One of R&D Directions 100 Great Investigational Drugs of 2009
NEW HAVEN, Conn., April 2 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc. ("Rib-X" or the "Company"), a development-stage company focused on the discovery and development of novel
antibiotics for the treatment of antibiotic-resistant infections, today announced that its lead compound, delafloxacin, ha...
Calixa Therapeutics Announces Positive Phase 1 Results for CXA-101, a Novel Intravenous Cephalosporin Antibiotic with Excellent Anti-Pseudomonal Activity
SAN DIEGO, March 24 /PRNewswire/ -- Calixa Therapeutics Inc. today announced positive results from a Phase 1 trial of intravenous CXA-101, a novel
cephalosporin antibiotic with excellent in vitro anti-pseudomonal activity.
The results from this first Phase 1 study demonstrated that CXA-101...
Hana Biosciences Announces Successful Planned Independent Safety Analysis Supports Ability to Complete Pivotal rALLy Clinical Trial of Marqibo, Its Lead Novel Anti-Cancer Compound
SOUTH SAN FRANCISCO, Calif., March 2 /PRNewswire-FirstCall/ -- Hana
Biosciences (Nasdaq: HNAB ) today announced that an Independent Data Monitoring
Committee (IDMC) has completed a planned, pre-specified safety review of interim
data from the ongoing pivotal rALLy clinical trial of Marqibo(R...
Endo Pharmaceuticals Announces Research Collaborations to Develop Novel Pain Treatments and Discover Potential Cancer Treatments
CHADDS FORD, Pa., Feb. 10 /PRNewswire-FirstCall/ -- Endo Pharmaceuticals (Nasdaq: ENDP ) announced today that it has signed two research collaboration agreements to develop novel
treatments for pain and to discover potential treatments for cancer.
The first collaboration, with Harvar...
Sequoia Pharmaceuticals Presents Proof of Clinical Concept of SPI-452, a Novel Pharmacokinetic Enhancer
MONTREAL, Feb. 9 /PRNewswire/ -- Sequoia Pharmaceuticals presented
positive results today from two phase 1 studies in healthy volunteers and
preclinical studies on SPI-452, a novel
pharmacokinetic enhancer (PKE) with no
inherent antiviral activity. Pharmacokinetic enhancers increase drug level...
Idenix Pharmaceuticals and GlaxoSmithKline Sign Worldwide License Agreement for IDX899, a Novel NNRTI for the Treatment of HIV
CAMBRIDGE, Mass. and LONDON, Feb. 6 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX ) and GlaxoSmithKline (GSK) today announced the execution of a license agreement granting GSK exclusive worldwide rights to IDX899. IDX899 is a novel
non-nucleoside reverse transcriptase inh...
Mardil Inc. Advances Its Novel Cardiac Device to First-In-Human Trials for Mitral Valve Regurgitation
RESEARCH TRIANGLE PARK, N.C., Jan. 26 /PRNewswire/ -- Mardil Inc., a cardiac device company with novel
technology for treating mitral valve regurgitation, has successfully advanced its device to first-in-human testing, a milestone achievement for the 2-year-old company.
The first patient was...
ThromboGenics and BioInvent Receive Technology Transfer Success Fee From Roche for the Novel Anti-Cancer Antibody, TB-403 (Anti-PIGF)
LEUVEN, Belgium and LUND, Sweden, January 26 /PRNewswire-FirstCall/ --
ThromboGenics NV (EURONEXT:THR) and BioInvent International AB (OMXS:BINV)
announce today that they have received a technology transfer success fee of
EUR5 million from Roche under the terms of their strategic alliance for ...
Cara Therapeutics Initiates Phase II Proof-Of-Concept Trial of Novel Analgesic in Acute Post-Operative Pain
SHELTON, Conn., Jan. 12 /PRNewswire/ -- Cara Therapeutics, Inc. today announced that it is initiating a Phase II clinical trial of its long-acting peripheral kappa opioid agonist, CR845. The Phase II multi-center, double-blind, placebo-controlled trial will be conducted in the United States and wi...
OmegaGenesis Unveils Novel Nanotechnology Platform With Broad Biomedical Applications
New Company Founded on Mayo Clinic Discoveries is Developing Therapies for Wounds, Diabetic Foot Ulcers and Hair Growth Using Nano-Materials with Angiogenic Properties
GILROY, Calif., Dec. 15 /PRNewswire/ -- OmegaGenesis today unveiled the company's novel
technology platform which employs...
Portola Pharmaceuticals Initiates Phase II Trial of Novel IV and Oral Anti-Platelet Drug in Non-Urgent Percutaneous Coronary Intervention
SOUTH SAN FRANCISCO, Calif., Dec. 9 /PRNewswire/ -- Portola
Pharmaceuticals, a biopharmaceutical company developing innovative drugs that
provide significant advances in cardiovascular disease, inflammatory disease
and cancer, today announced that it has initiated patient enrollment in
VentiRx Pharmaceuticals Commences Phase I Clinical Trial of VTX-2337, a Novel TLR8 Agonist for the Treatment of Oncology
First Selective TLR8 Agonist to Advance to Clinical Trials
SAN DIEGO, Dec. 4 /PRNewswire/ -- VentiRx Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of novel
Toll-Like Receptor 8 (TLR8) agonists for the treatment of cancer, respiratory and autoimmune diseases...
Sequoia Pharmaceuticals Presents In Vitro and First-in-Human Data Supporting Further Development of SPI-256, a Novel Investigational Protease Inhibitor
WASHINGTON, Oct. 26 /PRNewswire/ -- Sequoia Pharmaceuticals presented
positive results today from two studies on SPI-256, a novel
HIV protease inhibitor (PI). One study based on an in vitro analysis
demonstrates that the mode of interaction of SPI-256 with HIV protease
Addrenex Pharmaceuticals Initiates Phase 2 Trial on Its Novel Hypertension Drug, ADX415
New drug is company's third to enter human trials in 2 years
DURHAM, N.C., Oct. 23 /PRNewswire/ -- Addrenex Pharmaceuticals today
announced that the U.S. Food and Drug Administration has approved its
Investigational New Drug Application (IND) for ADX415, a novel
drug. With t...
Millennium Presents New Data on Investigational Drugs for Novel Cancer Targets at EORTC-NCI-AACR Symposium
CAMBRIDGE, Mass., Oct. 22 /PRNewswire/ -- Millennium: The Takeda
Oncology Company today announced new data from early non-clinical studies
of Millennium/Takeda-discovered pipeline molecules highlighting novel
therapeutic pathways in oncology. MLN4924 data build on the growing body of
CeNeRx BioPharma Initiates Phase II Clinical Trial of Its Novel Antidepressant Agent Tyrima(TM)
RESEARCH TRIANGLE PARK, N.C., Oct. 17 /PRNewswire/ -- CeNeRx BioPharma,
Inc., a clinical stage company developing and commercializing innovative
treatments for diseases of the central nervous system, today announced that
it has initiated a Phase II clinical trial for its lead product candidate...
deCODE Files IND for DG071, a Novel PDE4 Modulator Being Developed for Alzheimer's and Other Cognitive Disorders
REYKJAVIK, Iceland, Oct. 3 /PRNewswire-FirstCall/ -- deCODE genetics
(Nasdaq: DCGN ) today announced the filing of an investigational new drug
(IND) application for DG071, the company's novel
of phosphodiesterase 4 (PDE4), with the US Food and Drug Administration
Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society
Data support the therapeutic potential of Amylin's integrated neurohormonal approach to obesity pharmacotherapy
SAN DIEGO, Oct. 1 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals,
Inc. (Nasdaq: AMLN ) today announced that new data for its pipeline obesity
candidates will be pre...
NeoVista Unveils 18-month Data on Novel Wet AMD Therapy at Retina Society Meeting
Long-Term Phase II Data Continue to Highlight Potential of NeoVista's Epiretinal Brachytherapy
SCOTTSDALE, Ariz., Sept. 29 /PRNewswire/ -- NeoVista, Inc. made public
yesterday 18-month data from the company's Phase II feasibility study
examining its novel
Omeros and The Parkinson's Institute and Clinical Center Enter into a Collaboration Agreement to Evaluate Novel Target for the Treatment of Movement Disorders
SEATTLE and SUNNYVALE, Calif., Sept. 17 /PRNewswire/ -- Omeros
Corporation and The Parkinson's Institute and Clinical Center today
announced that they have entered into a collaboration to evaluate a novel
target, proprietary to Omeros, for the treatment of movement disorders. The
Spherics, Inc. Announces Reduced Cognitive Impairment of Novel Extended Release Topiramate (SRx-502) as Compared to Topamax(R)
Findings Presented At The American Society Of Clinical Psychopharmacology Meeting
WELLESLEY HILLS, Mass., Sept. 15 /PRNewswire/ -- Joseph F. Finn, Jr.,
C.P.A. ("Finn"), Assignee of the assets of Spherics, Inc. ("Spherics") for
the benefit of creditors, announced t...
Major State Grant Accelerates Research and Development of Novel Cancer Therapy
BOCA RATON, Fla., Sept. 5 /PRNewswire-USNewswire/ -- The Florida
Technology, Research and Scholarship Board recently awarded Florida
Atlantic University researcher Dr. Herbert Weissbach, distinguished
professor and director of the Center for Molecular Biology and
Biotechnology in the Charles E...
Volcano's VH(R) IVUS Technology Used in Imaging Study of GlaxoSmithKline's Novel Investigational Compound, Darapladib
IBIS-2 (Integrated Biomarker and Imaging Study) Results Demonstrate Benefits of VH(R) IVUS in Drug Development
SAN DIEGO, Calif., Sept. 2 /PRNewswire-FirstCall/ -- Volcano
Corporation (Nasdaq: VOLC ) [ESC Booth # A2-D403], a leading manufacturer of
intravascular ultrasound (IV...
Lixte Biotechnology Holdings Announces Filing of a New Patent Application for the Use of Novel Compounds as Potential Treatment for Neurodegenerative Diseases
EAST SETAUKET, N.Y., Aug. 12 /PRNewswire-FirstCall/ -- Lixte
Biotechnology Holdings, Inc. (OTC Bulletin Board: LIXT) announced today
that it had filed a patent application for the use of compounds the company
is developing for treatment of brain tumors as potential treatments for